Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
Erickson
J W
JW
Structural Biochemistry Program, SAIC-Frederick, National Cancer Institute-FCRDC, MD 21702, USA. erickson@ncifcrf.gov
Gulnik
S V
SV
Markowitz
M
M
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006801:Humans; D016879:Salvage Therapy
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors